Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSDZ 220-581
说明： Competitive NMDA antagonist
化学名： (S)-α-Amino-2'-chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid
纯度： ≥98% (HPLC)
生物活性 for SDZ 220-581
SDZ 220-581 is a competitive NMDA receptor antagonist (pKi = 7.7). Centrally active following oral administration (ED50 < 3.2 mg/kg for protection against MES-induced seizures).
许可信息
Sold with the permission of Novartis Pharma AG
技术数据 for SDZ 220-581
| 分子量 | 369.74 |
| 公式 | C16H17ClNO5P |
| 储存 | Store at RT |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 174575-17-8 |
| PubChem ID | 128019 |
| InChI Key | VBRJFXSFCYEZMQ-HNNXBMFYSA-N |
| Smiles | OC([C@@H](N)CC1=CC(C2=CC=CC=C2Cl)=CC(CP(O)(O)=O)=C1)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for SDZ 220-581
参考文献 for SDZ 220-581
参考文献是支持产品生物活性的出版物。
Bakshi et al (1999) Disruption of prepulse inhibition and increases in locomotor activity by competitive N-MthD.-aspartate receptor antagonists in rats. J.Pharmacol.Exp.Ther. 288 643 PMID: 9918570
Urwyler et al (1996) Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-MthD.-aspartate receptor antagonists - I. Pharmacological characterization in vitro. Neuropharmacology 35 643 PMID: 8887974
Urwyler et al (1996) Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-MthD.-aspartate receptor antagonists - II. Pharmacological characterization in vivo. Neuropharmacology 35 655 PMID: 8887975
按产品操作查看相关产品
关键词: SDZ 220-581, SDZ 220-581 supplier, Competitive, NMDA, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlur, Ionotropic, SDZ220-581, 1250, Tocris Bioscience
SDZ 220-581 的评论
目前没有该产品的评论。 Be the first to review SDZ 220-581 and earn rewards!
Have you used SDZ 220-581?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.